"compulsory licensing" | Khurana And Khurana Advocates and IP Attorneys

Compulsory licensing

3rd August, 2017 - 8:00 am Categories: India Intellectual Property Licensing Patents

Compulsory licenses are sovereign state authorizations which enable a third party to make, use, or sell a patented product without the consent of the patent holder. Provisions pertaining to compulsory licensing are provided for under both the Indian Patent Act, 1970, as well as the international legal agreement between all the member nations of WTO … Continue reading Compulsory licensing

Compulsory Licensing Application against the Patented Drug SAXAGLIPTIN by Lee Pharma

27th July, 2015 - 5:47 am Categories: India IP Practice in India News & Updates Patents pharma

0 Comments

Lee Pharma, a Hyderabad-based Indian pharma company, has filed a Compulsory Licensing (CL) Application (in accordance with Section 84(1) of the Indian Patents Act) against one of the patented drugs Saxagliptin for treating Diabetes Mellitus. The Patent on Saxagliptin was granted to Bristol Myers Squibb (BMS) in India on 30th April 2007 having number IN … Continue reading Compulsory Licensing Application against the Patented Drug SAXAGLIPTIN by Lee Pharma

Practice of Patent Asserting Entities: Boon or Bane: Global Innovations

20th October, 2014 - 8:55 am Categories: patent infringement Patent Litigation Patents

0 Comments

Introduction Patent troll relates to a person or company that enforces its patents against one or more alleged infringers in an opportunistic and unduly aggressive manner, often with no intention to manufacture or market the patented invention. Various terms such as patent trolls, patent monetization companies, or patent assertion entities are used for such entities; … Continue reading Practice of Patent Asserting Entities: Boon or Bane: Global Innovations

NATCO FILES INDIA’S FIRST COMPULSORY LICENSING APPLICATION

14th September, 2011 - 4:38 am Categories: Patent Commercialisation Pharma- biotech- Patent Commercialisation

0 Comments

Natco Pharma has filed India’s first Compulsory Licensing (CL) Application (in accordance with Section 84(1) of the Indian Patents Act) against one of the Bayer’s patented drug Sorafenib, marketed by Bayer as Nexavar for treating Kidney and Liver Cancer. Patent on Sorafenib is granted in India on 03.03.2008 having number IN 215758. This will be … Continue reading NATCO FILES INDIA’S FIRST COMPULSORY LICENSING APPLICATION

Tag: “compulsory licensing”